Bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) as a novel antileukemic agent with matrix metalloproteinase inhibitory activity

R. K. Narla, Y. Dong, D. Klis, F. M. Uckun

Research output: Contribution to journalArticlepeer-review

55 Scopus citations

Abstract

We have examined the in vitro anticancer activity of METVAN [bis(4,7-dimethyl-1,10 phenanthroline) sulfatooxovanadium(IV); VO(SO4)(Me2-Phen)2] against acute lymphoblastic leukemia (ALL; NALM-6 and MOLT-3), acute myeloid leukemia (AML; HL-60), Hodgkin's disease (HS445), and multiple myeloma (ARH-77, U266BL, and HS-SULTAN) cell lines as well as primary leukemic cells from patients with ALL, AML, and chronic acute myeloid leukemia (CML). METVAN induced apoptosis in NALM-6, MOLT-3, and HL-60 cells in a concentration-dependent fashion with EC50 values of 0.19 ± 0.03 μm, 0.19 ± 0.01 μM, and 1.1 ± 0.2 μM, respectively. METVAN induced apoptosis at low micromolar concentrations in primary leukemic cells from patients with ALL, AML, and CML. METVAN inhibited the constitutive expression of matrix metalloproteinase (MMP)-9 protein and its gelatinolytic activity in HL-60 cells and MMP-2 as well as MMP-9 gelatinolytic activities in leukemic cells from ALL, AML, and CML patients. Furthermore, METVAN inhibited the leukemic cell adhesion to the extracellular matrix proteins laminin, type IV collagen, vitronectin, and fibronectin and the invasion through Matrigel matrix. Further preclinical development of METVAN may provide the basis for the development of more effective chemotherapy programs.

Original languageEnglish (US)
Pages (from-to)1094-1101
Number of pages8
JournalClinical Cancer Research
Volume7
Issue number4
StatePublished - Aug 15 2001

Fingerprint Dive into the research topics of 'Bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) as a novel antileukemic agent with matrix metalloproteinase inhibitory activity'. Together they form a unique fingerprint.

Cite this